5-tert-butyl-1H-pyrrole-3-carbonitrile | 1240949-56-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 5-tert-butyl-1H-pyrrole-3-carbonitrile
• CAS: 1240949-56-7
• 化学式: C₉H₁₂N₂
• 分子量: 148.208
• InChiKey: MUVIBRHLAWBYKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  39.6
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• PROCESS FOR PRODUCING PYRROLE COMPOUND
  申请人：Ikemoto Tomomi

  公开号：US20110306769A1

  公开（公告）日：2011-12-15

  The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.

  本发明提供了一种作为药物产品有用的磺酰吡咯化合物的生产方法，一种用于该方法的中间体的生产方法，以及一种新的中间体。本发明涉及一种生产磺酰吡咯化合物（VIII）的方法，包括还原化合物（III）并水解还原产物以得到化合物（IV），将化合物（IV）经过磺酰化反应得到化合物（VI），并将化合物（VI）经过胺化反应。
• INHIBITORS OF C-FMS KINASE
  申请人：Janssen Pharmaceutica NV

  公开号：US20140378457A1

  公开（公告）日：2014-12-25

  The invention is directed to compounds of Formula I: wherein Z, X, J, R 2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及公式I的化合物：其中Z，X，J，R2和W如规范中所述，以及其溶剂化物，水合物，互变异构体和药物可接受的盐，可抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用公式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌，子宫癌，乳腺癌，前列腺癌，肺癌，结肠癌，胃癌，毛细胞白血病引起的转移；以及治疗疼痛，包括由肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏，炎症和神经源性疼痛；以及骨质疏松症，帕吉特病和其他骨吸收介导的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎，骨关节炎，假体失效，骨溶性肉瘤，骨髓瘤和肿瘤转移至骨骼。
• Process for producing pyrrole compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2765130A2

  公开（公告）日：2014-08-13

  The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.

  本发明提供了一种可用作医药产品的磺酰基吡咯化合物的生产方法、一种用于该方法的中间体的生产方法以及一种新型中间体。 本发明涉及磺酰基吡咯化合物（VIII）的生产方法，其中包括还原化合物（III）并水解还原产物得到化合物（IV），将化合物（IV）进行磺化反应得到化合物（VI），以及将化合物（VI）进行胺化反应。
• 5-aryl-1H-pyrrole-3-carbonitrile and a pharmaceutical product using the same
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10173977B2

  公开（公告）日：2019-01-08

  The present invention provides a production method of a sulfonylpyrrole compound useful as a pharmaceutical product, a production method of an intermediate used for the method, and a novel intermediate. The present invention relates to a method of producing sulfonylpyrrole compound (VIII), which includes reducing compound (III) and hydrolyzing the reduced product to give compound (IV), subjecting compound (IV) to a sulfonylation reaction to give compound (VI), and subjecting compound (VI) to an amination reaction.

  本发明提供了一种可用作医药产品的磺酰基吡咯化合物的生产方法、一种用于该方法的中间体的生产方法以及一种新型中间体。本发明涉及磺酰基吡咯化合物（VIII）的生产方法，其中包括还原化合物（III）并水解还原产物得到化合物（IV），将化合物（IV）进行磺化反应得到化合物（VI），以及将化合物（VI）进行胺化反应。
• Intermediates for use in a process of producing pyrrole compounds
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2765130B1

  公开（公告）日：2017-07-26